tbuckley/cabot-search huggingface dataset:
Epidemiologic and Clinical Analysis of Tumor Mutational Burden (TMB) in Acute Myeloid Leukemia (AML): Exome Sequencing Study of the Mayo Clinic AML Epidemiology Cohort (MCAEC)
Authors: James M. Foran, Michael G. Heckman, Yesesri Cherukuri, Mikolaj Wieczorek, Zaid Abdel Rahman, Liuyan Jiang, Hemant S. Murthy, Laura Finn, Talha Badar, Lisa Z. Sproat, Yanyan Lou, James R. Cerhan, Yan Asmann
Journal: Blood (2021)
Combination immunotherapy with nivolumab and ipilimumab in patients with rare gynecological malignancies: results of the CA209-538 clinical trial
Authors: Oliver Klein, Damien Kee, Bo Gao, Ben Markman, Jessica da Gama Duarte, Luke Quigley, Louise Jackett, Richelle Linklater, Andrew Strickland, Clare Scott, Linda Mileshkin, Jodie Palmer, Matteo Carlino, Andreas Behren, Jonathan Cebon
Journal: Journal for ImmunoTherapy of Cancer (2021)

Background Patients with rare cancers represent 55% of all gynecological malignancies and have poor survival outcomes due to limited treatment options. Combination immunotherapy with the anti-programmed cell death protein 1 (anti-PD-1) antibody nivolumab and the anti-cytotoxic T-lymphocyte-associated protein 4 (anti-CTLA-4) antibody ipilimumab has demonstrated significant clinical efficacy across a range of common malignancies, justifying evaluation of this combination in rare gynecological cancers. Methods This multicenter phase II study enrolled 43 patients with advanced rare gynecological cancers. Patients received induction treatment with nivolumab and ipilimumab at a dose of 3 mg/kg and 1 mg/kg, respectively, every 3 weeks for four doses. Treatment was continued with nivolumab monotherapy at 3 mg/kg every 2 weeks until disease progression or a maximum of 2 years. The primary endpoint was the proportion of patients with disease control at week 12 (complete response, partial response or stable disease (SD) by Response Evaluation Criteria In Solid Tumor V.1.1). Exploratory evaluations correlated clinical outcomes with tumor programmed death-ligand 1 (PD-L1) expression and tumor mutational burden (TMB). Results The objective response rate in the radiologically evaluable population was 36% (12/33 patients) and in the intention-to-treat population was 28% (12/43 patients), with additional 7 patients obtaining SD leading to a disease control rate of 58% and 44%, respectively. Durable responses were seen across a range of tumor histologies. Thirty-one (72%) patients experienced an immune-related adverse event (irAE) with a grade 3/4 irAE observed in seven (16%) patients. Response rate was higher among those patients with baseline PD-L1 expression (≥1% on tumor cells) but was independent of TMB. Conclusions Ipilimumab and nivolumab combination treatment has significant clinical activity with a favorable safety profile across a range of advanced rare gynecological malignancies and warrants further investigation in these tumor types.
Evolution of Genomic Landscape in Acute Myeloid Leukemia after Decitabine and Venetoclax
Authors: Abhishek Maiti, Courtney D. DiNardo, Naval Daver, Tapan M. Kadia, Gautam Borthakur, Nicholas J. Short, Naveen Pemmaraju, Maro Ohanian, Yesid Alvarado, Koichi Takahashi, Sherry A. Pierce, Keyur P. Patel, Elias J. Jabbour, Guillermo Garcia-Manero, Farhad Ravandi, Hagop Kantarjian, Marina Konopleva
Journal: Blood (2021)
Is it the moral duty of departments to cover shifts in the absence of staff?
Authors: George C Greenlees
Journal: BMJ (2021)

I was pleased to see all three respondents concur there is not a moral duty for doctors to cover shifts.1 Perhaps a follow-up article could ask if it’s the moral duty of departments to cover shifts in the absence of staff.

Not long ago, having picked up the on-call bleep at 8 am because of a rota gap, I de-scrubbed from a …
Evaluation of Early Treatment Response Utilizing the MAS-ALL18 Adapted Management Guideline in Four <i>"Mexico in Alliance with St. Jude"</i> (MAS) Member Hospitals
Authors: Hugo Romo, Pablo Gonzalez-Montalvo, Daniela Arce, Dinora Aguilar-Escobar, Nataly Mercado, Naomi Echeandia, Karla Nohemi Guerrero Gómez, Carlos Rodriguez-Galindo, Paola M. Friedrich
Journal: Blood (2021)
Safety and Effectiveness of Idelalisib in Patients with Double-Refractory Follicular Lymphoma: A Pan-European Cohort of 242 Patients
Authors: Emmanuel Gyan, Maria Chiara Tisi, Francesco Merli, Luca Baldini, Francesco Di Raimondo, Santiago Mercadal, Benedetta Puccini, Elisabeth Vandenberghe, Ka Lung Wu, Anthony Boland, Rikisha Shah Gupta, Anna van Troostenburg, Carolyn Dunnill, Heribert Ramroth, Nishanthan Rajakumaraswamy, Gilles Salles
Journal: Blood (2021)
Single-Cell Multi-Omic Analysis Uncovers Comprised Immune Function and Primary Resistance Mechanism in Acute Myeloid Leukemia
Authors: Jianbiao Zhou, Jonathan Adam Scolnick, Stacy Xu, Melissa Ooi, Priscella Shirley Chia, Sabrina Hui-Min Toh, Kalpnaa Balan, Michael Lovci, Tuan Zea Tan, Jen Wei Ying, Chin-Hin NG, Wee-Joo Chng
Journal: Blood (2021)
Safety and Efficacy of Letetresgene Autoleucel (lete-cel; GSK3377794) Alone or in Combination with Pembrolizumab in Relapsed and Refractory Multiple Myeloma
Authors: Taiga Nishihori, James E. Hoffman, Jonathan L. Kaufman, Anne Huff, Charlotte Snape, Amit Jain, Gurpreet Kapoor, Stefan Zajic, Sunil Suchindran, Michael Chisamore, Aaron P. Rapoport
Journal: Blood (2021)
Contemporary "Real World" Molecular Testing and Tyrosine Kinase Inhibitor Adherence Patterns Among Older Pts with Chronic Myeloid Leukemia in the United States
Authors: Rory M. Shallis, Rong Wang, Amer M. Zeidan, Scott F. Huntington, Natalia Neparidze, Mengyang Di, Xiaomei Ma, Nikolai Podoltsev
Journal: Blood (2021)
Molluskan Dorsal–Ventral Patterning Relying on BMP2/4 and Chordin Provides Insights into Spiralian Development and Evolution
Authors: Sujian Tan, Pin Huan, Baozhong Liu
Journal: Molecular Biology and Evolution (2021)

Abstract Although a conserved mechanism relying on BMP2/4 and Chordin is suggested for animal dorsal–ventral (DV) patterning, this mechanism has not been reported in spiralians, one of the three major clades of bilaterians. Studies on limited spiralian representatives have suggested markedly diverse DV patterning mechanisms, a considerable number of which no longer deploy BMP signaling. Here, we showed that BMP2/4 and Chordin regulate DV patterning in the mollusk Lottia goshimai, which was predicted in spiralians but not previously reported. In the context of the diverse reports in spiralians, it conversely represents a relatively unusual case. We showed that BMP2/4 and Chordin coordinate to mediate signaling from the D-quadrant organizer to induce the DV axis, and Chordin relays the symmetry-breaking information from the organizer. Further investigations on L. goshimai embryos with impaired DV patterning suggested roles of BMP signaling in regulating the behavior of the blastopore and the organization of the nervous system. These findings provide insights into the evolution of animal DV patterning and the unique development mode of spiralians driven by the D-quadrant organizer.
The Potential Roles of Mucosa-Associated Invariant T Cells in the Pathogenesis of Gut Graft-Versus-Host Disease after Hematopoietic Stem Cell Transplantation
Authors: Gao Mengge, Yan Hong, Zhao Xiangyu, Yuqian Sun, Jun Kong, Zhidong Wang, Fengrong Wang, Jingzhi Wang, Chenhua Yan, Yu Wang, Xiaojun Huang, Xiaosu Zhao
Journal: Blood (2021)
Developing nociceptor-selective treatments for acute and chronic pain
Authors: Selwyn Jayakar, Jaehoon Shim, Sooyeon Jo, Bruce P. Bean, Ilyas Singeç, Clifford J. Woolf
Journal: Science Translational Medicine (2021)

Phenotypic screens using human induced pluripotent stem cell–derived nociceptors hold promise for the development of better analgesics.
Mental Health Among Patients with Non-Hodgkin Lymphoma: A Danish Nationwide Study of Psychotropic Drug Use in 7,201 Patients and 36,005 Matched Comparators
Authors: Andreas Kiesbye Øvlisen, Lasse H. Jakobsen, Kristian Hay Kragholm, René Ernst Nielsen, Peter De Nully Brown, Rasmus Bo Dahl-Soerensen, Henrik Frederiksen, Nikolaj Mannering, Pär L. Josefsson, Ahmed Al-Mashhadi, Judit M. Jørgensen, Andriette Dessau-Arp, Michael Roost Clausen, Robert Schou Pedersen, Christian Torp-Pedersen, Marianne Tang Severinsen, Tarec Christoffer El-Galaly
Journal: Blood (2021)
Zanubrutinib, Obinutuzumab, and Venetoclax in Chronic Lymphocytic Leukemia: Early MRD Kinetics Define a High-Risk Patient Cohort with Delayed Bone Marrow Undetectable MRD and Earlier Post-Treatment MRD Recurrence
Authors: Jacob D. Soumerai, Anthony R. Mato, Ahmet Dogan, Venkatraman Seshan, Erel Joffe, Kelsey Flaherty, Jason Carter, Ephraim P Hochberg, Jeffrey A Barnes, Audrey Hamilton, Jeremy S. Abramson, Connie Lee Batlevi, Matthew J. Matasar, Ariela Noy, Colette Owens, M. Lia Palomba, Anita Kumar, Tak Takvorian, Ai Ni, Morgan Choma, Chaya Friedman, Puja Chadha, Elizabeth Simkins, Jade Ruiters, Sidney Sechio, Daneal Portman, Natascha Nolet, Neena Mahajan, Rosalba Martignetti, Joanna Mi, Krista J Scorsune, Julia M Lynch, Brianne McGree, Stephanie Y Hughes, Clare Grieve, Lindsey E. Roeker, Meghan C. Thompson, P. Connor Johnson, Mikhail Roshal, Jane Huang, Juliana M.L. Biondo, Jenny Qun Wu, Allison P. Jacob, Omar Abdel-Wahab, Andrew D. Zelenetz
Journal: Blood (2021)
Prophylactic Treatment with Rurioctocog Alfa Pegol Results in a Dose-Dependent Normalization of Biomarkers of Joint Health in Severe Hemophilia a: An Exploratory Analysis from the Propel Study
Authors: Tina Manon-Jensen, Srilatha Tangada, Cecilie Bager, Pratima Chowdary, Robert Klamroth, Annette von Drygalski, Jerzy Windyga, Miguel A. Escobar, Peder Frederiksen, Werner Engl, Bruce Ewenstein, Morten Karsdal
Journal: Blood (2021)
CLR 131 (Iopofosine I-131) Treatment in Triple Class Refractory and Beyond Multiple Myeloma Patients: Preliminary Efficacy and Safety Results from the Phase 2 Clover-1 Trial
Authors: Sikander Ailawadhi, Patrick Stiff, Emad Ibrahim, Damian J. Green, Brea Lipe, Elizabeth H. Cull, Natalie S. Callander, John Friend, Jarrod Longcor, Kate Oliver
Journal: Blood (2021)
Role of membrane proteins in bacterial resistance to antimicrobial peptides
Authors: Vladimir Vimberg, Karolína Buriánková, Aninda Mazumdar, Pavel Branny, Gabriela B. Novotná
Journal: Medicinal Research Reviews (2021)

Several natural antimicrobial peptides (AMPs), including the novel semisynthetic lipoglycopeptide antibiotics telavancin, dalbavancin, and oritavancin, have been approved for clinical use to address the growing problem of multiple antibiotic-resistant Gram-positive bacterial infections. Nevertheless, the efficacy of these antibiotics has already been compromised. The SARS-CoV-2 pandemic led to the increased clinical use of all antibiotics, further promoting the development of bacterial resistance. Therefore, it is critical to gain a deeper understanding of the role of resistance mechanisms to minimize the consequential risks of long-term antibiotic use and misuse. Here, we summarize for the first time the current knowledge of resistance mechanisms that have been shown to cause resistance to clinically used AMPs, with particular focus on membrane proteins that have been reported to interfere with the activity of AMPs by affecting the binding of AMPs to bacteria.
Abstract 13127: Concordance in Nutrient Biomarker and Cardiometabolic Risk Factors Between Child-Parent Dyads Participating in a Family-Based Childhood Weight Management Intervention
Authors: Nirupa R Matthan, Kathryn Barger, Tsai Chia-Fang, Judith Wylie-Rosett, Adriana E Groisman-Perelstein, Pamela M Diamantis, Xiaonan Xue, Yasmin Mossavar-Rahmani, Mindy Ginsberg, Alice H Lichtenstein
Journal: Circulation (2021)

Introduction: Children are at elevated risk for developing obesity/cardiometabolic abnormalities when their parents have these conditions. Little is known about diet quality and subsequent impact on cardiometabolic risk factors (CMRFs) in child-parent dyads. Objective: To determine the concordance between nutrient biomarkers and CMRF changes in children (age 7-12 years; BMIz &gt;85%tile) and their parents, who participated in a 1-year randomized controlled trial designed to evaluate the effects of adding an enhanced program to standard care. Methods: Pre-post intervention changes in nutrient biomarkers (plasma carotenoids; RBC fatty acid profiles) and CMRFs (BMI, blood pressure, and plasma glucose, insulin, lipid profile, inflammatory markers and adipokine concentrations) were evaluated in 226 child-parent dyads. Based on percent change in children’s BMIz score, they were grouped into high ( &gt; -8%), medium (0 to -8%) and low ( &gt; 0%) responders. Spearman’s correlation coefficients were calculated to determine association between 1-year change in nutrient biomarkers and CMRFs within child-parent dyad groups. Results: There were positive associations in beta-carotene, and RBC SFA, MUFA, PUFA n-6, PUFA n-3 and trans fatty acid concentrations in child-parent dyads, regardless of group ( r= 0.25 to 0.83, p&lt;0.05). Significant positive child-parent associations were observed for systemic (TNFa, IL-1, IL-6) and vascular (E- and P-selectin, thrombomodulin) inflammatory markers (r= 0.32 to 0.83, p&lt;0.05), and adiponectin (r=0.47, p=0.001), but not other CMRFs. In the high responder group, there was a positive association between improvements in child’s BMIz scores and parental BMI (r=0.32, p=0.01). This dyad also had the most favorable improvements in nutrient biomarkers (increases in carotenoids, and decreases in SFA and trans fatty acids) and CMRFs (decreases in blood pressure, and LDL-C, TG and hsCRP concentrations). Conclusions: Our finding of concordance in child-parent dyad changes in nutrient biomarkers and selected CMRFs after a 1-year intervention, especially in the high responder group, suggests parallel dietary changes and highlights the importance of parental engagement in the effectiveness of childhood obesity interventions.
SARS-CoV-2 interaction with Siglec-1 mediates trans-infection by dendritic cells
Authors: Daniel Perez-Zsolt, Jordana Muñoz-Basagoiti, Jordi Rodon, Marc Elosua-Bayes, Dàlia Raïch-Regué, Cristina Risco, Martin Sachse, Maria Pino, Sanjeev Gumber, Mirko Paiardini, Jakub Chojnacki, Itziar Erkizia, Xabier Muñiz-Trabudua, Ester Ballana, Eva Riveira-Muñoz, Marc Noguera-Julian, Roger Paredes, Benjamin Trinité, Ferran Tarrés-Freixas, Ignacio Blanco, Victor Guallar, Jorge Carrillo, Julià Blanco, Amalio Telenti, Holger Heyn, Joaquim Segalés, Bonaventura Clotet, Javier Martinez-Picado, Júlia Vergara-Alert, Nuria Izquierdo-Useros
Journal: Cellular and Molecular Immunology (2021)
Relmacabtagene Autoleucel CD19 CART Therapy for Adults with Heavily-Pretreated Relapsed/Refractory Large B-Cell Lymphoma in China
Authors: Yuqin Song, Zhitao Ying, Haiyan Yang, Ye Guo, Wenyu Li, Dehui Zou, Daobin Zhou, Zhao Wang, Mingzhi Zhang, Jianqiu Wu, Hui Liu, Pian Zhang, Su Yang, Zisong Zhou, Hongxia Zheng, Jun Zhu
Journal: Blood (2021)
Clinical, Echocardiographic, and Biomarker Associations With Impaired Cardiorespiratory Fitness Early After HER2-Targeted Breast Cancer Therapy
Authors: Alis Bonsignore, Thomas H. Marwick, Scott C. Adams, Babitha Thampinathan, Emily Somerset, Eitan Amir, Mike Walker, Husam Abdel-Qadir, C. Anne Koch, Heather J. Ross, Anna Woo, Bernd J. Wintersperger, Mark J. Haykowsky, Paaladinesh Thavendiranathan
Journal: JACC CardioOncology (2021)

Cardiorespiratory fitness (CRF) is reduced in cancer survivors and predicts cardiovascular disease (CVD)-related and all-cause mortality. However, routine measurement of CRF is not always feasible.The purpose of this study was to identify clinical, cardiac biomarker, and imaging measures associated with reduced peak oxygen consumption (VO2peak) (measure of CRF) early post-breast cancer therapy to help inform CVD risk.Consecutive women with early-stage HER2+ breast cancer receiving anthracyclines and trastuzumab were recruited prospectively. Within 6 ± 2 weeks of trastuzumab completion, we collected clinical information, systolic/diastolic echocardiographic measures, high-sensitivity troponin I, B-type natriuretic peptide, and VO2peak using a cycle ergometer. Regression models were used to examine the association between VO2peak and clinical, imaging, and cardiac biomarkers individually and in combination.Among 147 patients (age 52.2 ± 9.3 years), the mean VO2peak was 19.1 ± 5.0 mL O2·kg-1·min-1 (84.2% ± 18.7% of predicted); 44% had a VO2peak below threshold for functional independence (<18 mL O2·kg-1·min-1). In multivariable analysis, absolute global longitudinal strain (GLS) (β = 0.58; P = 0.007), age per 10 years (β: -1.61; P = 0.001), and E/e' (measure of diastolic filling pressures) (β = -0.45; P = 0.038) were associated with VO2peak. GLS added incremental value in explaining the variability in VO2peak. The combination of age ≥50 years, E/e' ≥7.8, and GLS <18% identified a high probability (85.7%) of compromised functional independence, whereas age <50 years, E/e' <7.8, and GLS ≥18% identified a low probability (0%). High-sensitivity troponin I and B-type natriuretic peptide were not associated with VO2peak.Readily available clinical measures were associated with VO2peak early post-breast cancer therapy. A combination of these parameters had good discrimination to identify patients with compromised functional independence and potentially increased future CVD risk.
Association of Adiposity With Mortality Among Black Patients With Breast Cancer—Reply
Authors: Elisa V. Bandera, Bo Qin, Chi-Chen Hong
Journal: JAMA Oncology (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Brain physiome: A concept bridging in vitro 3D brain models and in silico models for predicting drug toxicity in the brain
Authors: Yoojin Seo, Seokyoung Bang, Jeongtae Son, Dongsup Kim, Yong Jeong, Pilnam Kim, Jihun Yang, Joon-Ho Eom, Nakwon Choi, Hong Nam Kim
Journal: Bioactive Materials (2021)

In the last few decades, adverse reactions to pharmaceuticals have been evaluated using 2D
A Phase II Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Efficacy of Cmvpepvax for Preventing CMV Reactivation/Disease after Matched Related/Unrelated Donor Hematopoietic Cell Transplant
Authors: Ryotaro Nakamura, Corinna La Rosa, Dongyun Yang, Joshua A. Hill, Armin Rashidi, Hannah Choe, Qiao Zhou, Chetan Raj Lingaraju, Jeffrey Longmate, Jennifer Drake, Cynthia Slape, Lupe Duarte, Monzr M. Al Malki, Vinod A. Pullarkat, Ahmed Aribi, Thai Cao, Steven Devine, Michael R Verneris, Jeffrey S. Miller, Stephen J Forman, Ibrahim Aldoss, Don J. Diamond
Journal: Blood (2021)
Screening for Hereditary Alpha-Tryptasemia in Subjects with Systemic Mastocytosis (SM) and Non-SM Mast Cell Activation Symptoms
Authors: Fiorenza Irushani Vanderwert, Benedetta Sordi, Francesco Mannelli, Boaz Palterer, Francesca Gesullo, Valentina Mecheri, Raffaella Santi, Carmela Mannarelli, Francesca Crupi, Roberta Zanotti, Federica Irene Grifoni, Chiara Elena, Roberta Parente, Massimo Triggiani, Pieri Lisa, Fabio Almerigogna, Paola Guglielmelli, Alessandro Vannucchi
Journal: Blood (2021)
Multinational Study on the Clinical and Genetic Features of the ERCC6L2-Disease
Authors: Marja Hakkarainen, Suvi P. M. Douglas, Tom Vulliamy, Inderjeet Dokal, Jean Soulier, Lise Larcher, Riitta Niinimäki, Timo Siitonen, Eva Hellstrom Lindberg, Gisela Barbany, Bianca Tesi, Amir Asher Kuperman, Hannah Tamary, Sharon Jackson, Outi Kilpivaara, Ulla Wartiovaara-Kautto
Journal: Blood (2021)
Iberdomide (IBER) in Combination with Dexamethasone (DEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Dose-Expansion Phase of the CC-220-MM-001 Trial
Authors: Sagar Lonial, Rakesh Popat, Cyrille Hulin, Sundar Jagannath, Albert Oriol, Paul G. Richardson, Thierry Facon, Katja Weisel, Jeremy T. Larsen, Monique C. Minnema, Al-Ola Abdallah, Ashraf Z. Badros, Stefan Knop, Edward A. Stadtmauer, Min Chen, Tuong Vi Nguyen, Alpesh Amin, Elisabeth Kueenburg, Teresa Peluso, Niels W.C.J. van de Donk
Journal: Blood (2021)
Lyme neuroborreliosis with encephalitis; a systematic literature review and a Scandinavian cohort study
Authors: Fredrikke Christie Knudtzen, Randi Eikeland, Daniel Bremell, Else Quist-Paulsen, Isik Somuncu Johansen, Anne-Marit Solheim, Sigurdur Skarphédinsson
Journal: Clinical Microbiology and Infection (2021)

Lyme neuroborreliosis (LNB) presenting with encephalitis is rare and scarcely described.To describe the available literature on LNB encephalitis and to characterize this patient group through a Scandinavian retrospective cohort study.Medline, Embase, Scopus, Cochrane library.There was no discrimination on study type, time of publication or language.Review: All articles with definite LNB and confirmed/possible encephalitis.LNB cohorts from Denmark, Sweden and Norway 1990-2019 were screened for patients with encephalitis.Review: Adhering to PRISMA guidelines; two authors extracted reviews and assessed quality of studies.Data on demography, symptoms, cerebrospinal fluid findings, differential diagnostic examinations, treatment, residual symptoms, 1-year mortality were registered.Review: 2330 articles screened on title/abstract, 281 full texts, yielding 42 articles (case reports/series or cohort studies), including 45 patients from 18 countries spanning 35 years. Altered mental status ranged from personality changes and confusion to unconsciousness. Common focal symptoms were hemiparesis, ataxia and dysarthria; seven patients had seizures. Median time from symptom onset to hospital was 2 weeks (IQR 2-90 days). Of 38 patients with available follow-up after median 12 months (IQR 5-13), 32 had fully or partially recovered, two had died.Thirty-five patients (median age 67 years, IQR 48-76) were included. The encephalitis prevalence was 3.3% (95% CI 2.2-4.4%) among 1019 screened LNB patients. Frequent encephalitis symptoms were confusion, personality changes, aphasia, ataxia. EEGs and neuroimaging showed encephalitis in 93.8% and 20.6%, respectively. Median delay from symptom onset to hospital was 14 days (IQR 7-34), with further 7 days (IQR 3-34) delay until targeted therapy. At follow-up (median 298 days post-treatment; IQR 113-389), 65.6% had residual symptoms. None had died.This study shows that encephalitis is an uncommon, but likely overlooked clinical manifestation of LNB. As the high frequency of residual symptoms may be related to prolonged treatment delay, prompt LNB testing of patients with encephalitis in Borrelia burgdorferi-endemic areas should be considered.
Human Genetic Diversity Alters Therapeutic Gene Editing Off-Target Outcomes
Authors: Linda Yingqi Lin, Samuele Cancellieri, Jing Zeng, Francesco Masillo, My Anh Nguyen, Nicola Bombieri, Stacy A. Maitland, Marioara-Felicia Ciuculescu, Varun Katta, Shengdar Q. Tsai, Myriam Armant, Scot A. Wolfe, Rosalba Giugno, Luca Pinello, Daniel E. Bauer
Journal: Blood (2021)